Evidence map›Paper›PMID 34694226›Full record

ArticleeLife2021

Effect of SARS-CoV-2 proteins on vascular permeability.

Rossana Rauti, Meishar Shahoha, Yael Leichtmann-Bardoogo, Rami Nasser, Eyal Paz, Rina Tamir, Victoria Miller, Tal Babich, Kfir Shaked, Avner Ehrlich and 5 more

Open access · goldAbstract read
In one paragraph

Article in eLife, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed
4.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 81 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 2 countries.

Rossana Rauti *Department of Biomedical Engineering, Tel Aviv University, Tel Aviv, Israel.ORCID 0000-0001-8569-0810
Meishar Shahoha *School of Neurobiology, Biochemistry and Biophysics, The George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel.ORCID 0000-0001-5947-484X
Yael Leichtmann-Bardoogo *Department of Biomedical Engineering, Tel Aviv University, Tel Aviv, Israel.
Rami NasserBlavatnik School of Computer Science, Tel Aviv University, Tel Aviv, Israel.
Eyal PazSchool of Neurobiology, Biochemistry and Biophysics, The George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel.
Rina TamirDepartment of Biomedical Engineering, Tel Aviv University, Tel Aviv, Israel.
Victoria MillerDepartment of Biomedical Engineering, Tel Aviv University, Tel Aviv, Israel.
Tal BabichDepartment of Biomedical Engineering, Tel Aviv University, Tel Aviv, Israel.
Kfir ShakedDepartment of Biomedical Engineering, Tel Aviv University, Tel Aviv, Israel.
Avner EhrlichGrass Center for Bioengineering, The Hebrew University of Jerusalem, Jerusalem, Israel.
Konstantinos IoannidisGrass Center for Bioengineering, The Hebrew University of Jerusalem, Jerusalem, Israel.
Yaakov NahmiasGrass Center for Bioengineering, The Hebrew University of Jerusalem, Jerusalem, Israel.
Roded SharanBlavatnik School of Computer Science, Tel Aviv University, Tel Aviv, Israel.
Uri AsherySchool of Neurobiology, Biochemistry and Biophysics, The George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel.ORCID 0000-0001-6338-7888
Ben Meir MaozDepartment of Biomedical Engineering, Tel Aviv University, Tel Aviv, Israel.ORCID 0000-0002-3823-7682
Tel Aviv University · ILHebrew University of Jerusalem · IL

Funding

Deutsche Forschungsgemeinschaft 207/10-1Horizon 2020 SweetBrain 851765Israel Science Foundation 2248/19Israel Science Foundation 953/16Ministry of Science and Technology, Israel 3-17351
6 · The paper itself

Abstract

Severe acute respiratory syndrome (SARS)-CoV-2 infection leads to severe disease associated with cytokine storm, vascular dysfunction, coagulation, and progressive lung damage. It affects several vital organs, seemingly through a pathological effect on endothelial cells. The SARS-CoV-2 genome encodes 29 proteins, whose contribution to the disease manifestations, and especially endothelial complications, is unknown. We cloned and expressed 26 of these proteins in human cells and characterized the endothelial response to overexpression of each, individually. Whereas most proteins induced significant changes in endothelial permeability, nsp2, nsp5_c145a (catalytic dead mutant of nsp5), and nsp7 also reduced CD31, and increased von Willebrand factor expression and IL-6, suggesting endothelial dysfunction. Using propagation-based analysis of a protein-protein interaction (PPI) network, we predicted the endothelial proteins affected by the viral proteins that potentially mediate these effects. We further applied our PPI model to identify the role of each SARS-CoV-2 protein in other tissues affected by coronavirus disease (COVID-19). While validating the PPI network model, we found that the tight junction (TJ) proteins cadherin-5, ZO-1, and β-catenin are affected by nsp2, nsp5_c145a, and nsp7 consistent with the model prediction. Overall, this work identifies the SARS-CoV-2 proteins that might be most detrimental in terms of endothelial dysfunction, thereby shedding light on vascular aspects of COVID-19.

Indexed as

Capillary PermeabilityHost-Pathogen InteractionsAnimalsCOVID-19Endothelium, VascularHumansHuman Umbilical Vein Endothelial CellsProtein Interaction MapsSARS-CoV-2Tight Junction ProteinsViral ProteinsTight Junction ProteinsViral Proteinsendotheliumhumaninfectious diseasemicrobiologyprotein interactionsSARS-COV-2vasculature

Identifiers

PMID34694226
PMCPMC8545399
OpenAlexW3208991691

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.